Differentiation of HUC-MSC into Dopaminergic-like Cells After Transduction with Hepatocyte Growth Factor

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2013 Jun 6

PMID 23737134

Citations 19

Authors

Jin-Feng Li

Hong-Lei Yin

Adam Shuboy

Hai-Feng Duan

Ji-Yu Lou

Jing Li

Hong-Wei Wang

Yun-Liang Wang

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a common neurodegenerative condition causing significant disability and thus negatively impacting quality of life. The recent advent of stem cell-based therapy has heralded the prospect of a potential restorative treatment option for PD. In particular, mesenchymal stem cells derived from human umbilical cord (hUC-MSCs) have great potential for developing a therapeutic agent as such. Furthermore, hepatocyte growth factor (HGF), which shows mitogenic and morphogenetic activities in a variety of cells, including MSC, and may be implicated in the pathophysiology of PD. As such, HGF may represent a new therapeutic target for the disease. In this study, we successfully isolated and facilitated the transduction of an adenoviral vector expressing HGF (Ad-HGF) into isolated hUC-MSCs. Following transduction, the hUC-MSCs can differentiate into dopaminergic neuron-like cells secreting dopamine, tyrosine hydroxylase, and dopamine transporter. Our data suggest that hUC-MSCs have the ability to differentiate into dopaminergic neurons after transduction with Ad-HGF, providing encouraging evidence to further explore this approach to the treatment of PD.

Citing Articles

Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease.

Ekrani S, Mahmoudi M, Haghmorad D, Kheder R, Hatami A, Esmaeili S Stem Cell Res Ther. 2024; 15(1):476.

PMID: 39696636 PMC: 11657756. DOI: 10.1186/s13287-024-04073-9.

Predominant control of PDGF/PDGF receptor signaling in the migration and proliferation of human adipose‑derived stem cells under culture conditions with a combination of growth factors.

Sun Z, Fukui M, Taketani S, Kako A, Kunieda S, Kakudo N Exp Ther Med. 2024; 27(4):156.

PMID: 38476902 PMC: 10928992. DOI: 10.3892/etm.2024.12444.

Potential Application of Orofacial MSCs in Tissue Engineering Nerve Guidance for Peripheral Nerve Injury Repair.

Meng Q, Burrell J, Zhang Q, Le A Stem Cell Rev Rep. 2023; 19(8):2612-2631.

PMID: 37642899 DOI: 10.1007/s12015-023-10609-y.

Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings.

Meng H, Jin J, Wang H, Wang L, Wu C J Cell Mol Med. 2022; 26(18):4745-4755.

PMID: 35922965 PMC: 9465188. DOI: 10.1111/jcmm.17497.

Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial.

Yao X, Xie L, Cai Y, Zhang Y, Deng Y, Gao M Front Neurol. 2022; 13:860083.

PMID: 35547390 PMC: 9082633. DOI: 10.3389/fneur.2022.860083.

References

Michalopoulos G, Zarnegav R . Hepatocyte growth factor. Hepatology. 1992; 15(1):149-55. DOI: 10.1002/hep.1840150125. View

Corbitt J, Hagerty T, Fernandez E, Morgan W, Strong R . Transcriptional and post-transcriptional regulation of tyrosine hydroxylase messenger RNA in PC12 cells during persistent stimulation by VIP and PACAP38: differential regulation by protein kinase A and protein kinase C-dependent pathways. Neuropeptides. 2002; 36(1):34-45. DOI: 10.1054/npep.2002.0885. View

Ali S, Binienda Z, Imam S . Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction. Int J Environ Res Public Health. 2012; 8(12):4702-13. PMC: 3290988. DOI: 10.3390/ijerph8124702. View

Harrington K, Augood S, Kingsbury A, Foster O, Emson P . Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res. 1996; 36(1):157-62. DOI: 10.1016/0169-328x(95)00278-z. View

Bae S, Shim S, Park C, Son H, Lee H, Son J . Combined omics analysis identifies transmembrane 4 L6 family member 1 as a surface protein marker specific to human mesenchymal stem cells. Stem Cells Dev. 2010; 20(2):197-203. DOI: 10.1089/scd.2010.0127. View

Koike H, Ishida A, Shimamura M, Mizuno S, Nakamura T, Ogihara T . Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease. Gene Ther. 2006; 13(23):1639-44. DOI: 10.1038/sj.gt.3302810. View

Kim S, Jeon B, Heo C, Im P, Ahn T, Seo J . Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J. 2004; 18(13):1615-7. DOI: 10.1096/fj.04-1917fje. View

Pluck G, Brown R . Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002; 73(6):636-42. PMC: 1757348. DOI: 10.1136/jnnp.73.6.636. View

Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J . Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol. 2011; 272(1):33-8. PMC: 3235326. DOI: 10.1016/j.cellimm.2011.09.010. View

10.

Halfon S, Abramov N, Grinblat B, Ginis I . Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 2010; 20(1):53-66. DOI: 10.1089/scd.2010.0040. View

11.

Flici H, Giangrande A . Stem cell aging and plasticity in the Drosophila nervous system. Fly (Austin). 2012; 6(2):108-12. DOI: 10.4161/fly.19797. View

12.

Philippova M, Suter Y, Toggweiler S, Schoenenberger A, Joshi M, Kyriakakis E . T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur Heart J. 2010; 32(6):760-71. DOI: 10.1093/eurheartj/ehq206. View

13.

Duan H, Wu C, Wu D, Lu Y, Liu H, Ha X . Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther. 2003; 8(3):467-74. DOI: 10.1016/s1525-0016(03)00186-2. View

14.

Rascol O, Lozano A, Stern M, Poewe W . Milestones in Parkinson's disease therapeutics. Mov Disord. 2011; 26(6):1072-82. DOI: 10.1002/mds.23714. View

15.

Bottaro D, Rubin J, Faletto D, Chan A, Kmiecik T, Woude G . Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251(4995):802-4. DOI: 10.1126/science.1846706. View

16.

Lan F, Xu J, Zhang X, Wong V, Li X, Lu A . Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells. Neuroreport. 2008; 19(7):765-9. DOI: 10.1097/WNR.0b013e3282fdf69e. View

17.

Kastner A, Hirsch E, Agid Y . Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res. 1993; 606(2):341-5. DOI: 10.1016/0006-8993(93)91005-d. View

18.

Hu Z, Geng J, Liang D, Luo M, Li M . Hepatocyte growth factor protects human embryonic stem cell derived-neural progenitors from hydrogen peroxide-induced apoptosis. Eur J Pharmacol. 2010; 645(1-3):23-31. DOI: 10.1016/j.ejphar.2010.07.011. View

19.

Kish S, Shannak K, Hornykiewicz O . Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318(14):876-80. DOI: 10.1056/NEJM198804073181402. View

20.

Fox S, Chuang R, Brotchie J . Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res. 2008; 172:479-94. DOI: 10.1016/S0079-6123(08)00923-0. View